California Poppy Sleep Studies Tested Rats, Then Guessed at Human Doses

The Oasis Health Journal · Submitted September 26, 2026 · 3:00 PM EDT

By June Mackerel · Edited by Colette Ward

California poppy, Eschscholzia californica, is sold as a natural sleep aid on the basis of research that measured enzyme inhibition in test tubes, sedation in rodents, and then arrived at human dosing recommendations without, apparently, pausing to establish whether any of the active compounds actually reach a person's brain after swallowing a capsule. The california poppy sleep supplement industry appears to have skipped pharmacokinetics entirely and gone straight to the label printer, which is efficient from a business perspective but rather less so from a scientific one.

What the Research Measured, and What It Did Not

A 2025 metabolomic analysis identified seventy compounds in four different extracts of the aerial parts of California poppy. The list included kaempferol derivatives, rutin, quercetin, caffeic acid, quinoline alkaloids, morphine derivatives, and scoulerine. One imagines the researchers were quite pleased with themselves. They then tested these extracts for antioxidant capacity, enzyme inhibition, and cytotoxic activity against cancer cells. The ethanol extract inhibited acetylcholinesterase at a rate of 2.39 milligrams gallic acid equivalents per gram. The ethyl acetate extract inhibited butyrylcholinesterase at 3.31 milligrams per gram.

These are enzymes, not sleep.

The same team conducted in silico docking studies and determined that protopine, rutin, eschscholtzidine, boldine, and scoulerine exhibited notable inhibitory effects on proteins associated with insomnia, specifically DRD5, DRD4, and the serotonin transporter. This is computer modelling, which is to say a sophisticated guess about whether a molecule might fit into a binding pocket if the two ever met under ideal conditions, rather like speculating whether a man would fit through a doorway without bothering to check if he ever walks toward the door, or indeed whether the door exists in the same building, or the same country. Not quite the same as demonstrating that they do meet, or that the meeting matters, or that a person experiences any of this after swallowing a capsule with breakfast.

At no point in the paper do the words 'pharmacokinetics', 'bioavailability', or 'oral absorption' appear. I checked twice.

The Animal Work, and the Rather Large Leap That Followed

A 2022 safety study tested protopine, one of the alkaloids present in California poppy, in a placental cell line at concentrations ranging from 0.1 to 30 micromolar. The researchers reported that protopine was 'inconspicuous in all experiments and showed no adverse effects'. This is what one says about wallpaper, not about a molecule one intends to consume for its purported effects on brain chemistry.

The study concluded that extracts from California poppy are 'likely to be safe during pregnancy', though the qualifier 'likely' does quite a lot of heavy lifting here, as does the reliance on in vitro work and the complete absence of any human trial data. The authors acknowledged that high plasma concentrations of certain compounds deserve special attention, but they did not measure any plasma concentrations, so it is unclear what concentration would qualify as high, or indeed whether any concentration whatsoever is reached after oral dosing in a human being. A modest gap in the evidence, then.

The supplement industry, undeterred by such gaps, or indeed by gaps of any kind, proceeded to bottle the extract and print dosing instructions on the label.

The One Human Trial, Which Tested Two Herbs at Once

A 2020 observational study enrolled adults with adjustment insomnia and gave them up to four tablets per night of a fixed combination of California poppy and valerian extracts. After four weeks, insomnia severity index scores decreased from 16.09 to 11.32, a drop of approximately thirty percent. Night sleep duration increased. Sleep efficiency improved from 78.4 percent to 84.6 percent. The number of awakenings decreased by about twenty-five percent, and their total duration dropped by roughly twenty-five minutes. Anxiety scores fell by fifty percent.

This was not a randomised controlled trial. There was no placebo. There was no blinding. The participants knew they were taking something meant to help them sleep, and people who believe they are being treated for insomnia often report sleeping better, whether or not the capsule contains anything pharmacologically active. This is well-documented. It is also rather inconvenient for anyone wishing to attribute the improvement specifically to the herbs.

More to the point, the trial tested a combination of two plants. Valerian has its own set of sedative compounds, including valerenic acid, which was tested separately in the 2022 safety study and found to be similarly inconspicuous, though again one wonders whether inconspicuous is quite the selling point the industry believes it to be. Attempting to determine how much of the observed effect was due to California poppy, how much to valerian, and how much to belief would require a rather more rigorous design than was employed here, perhaps involving a control group, or at the very least a coin toss. The study does not attempt such a determination. It simply reports that people felt better and concludes that the combination 'could be beneficial'.

That conclusion stops well short of establishing efficacy for either ingredient individually, let alone establishing an appropriate dose for California poppy on its own, which one might have thought would be the point of the exercise.

The Dosing Question, Which Remains Unanswered

The 2020 observational study allowed participants to take up to four tablets nightly, but the paper does not specify how much California poppy extract each tablet contained, nor does it report how many milligrams of any individual alkaloid were present. The 2025 metabolomic study identified the compounds and measured their activity in vitro, but it did not dose animals, and it certainly did not dose people. The 2022 safety study tested individual alkaloids in cell culture at concentrations expressed in micromolar, which is a useful unit for laboratory work and entirely useless for someone standing in a shop trying to decide how much California poppy to take.

The process appears to have gone like this: researchers identified alkaloids, observed that they inhibited certain enzymes or bound to certain receptors in silico, tested them in cells or animals, noted sedative effects, and then someone, somewhere, perhaps in a formulation meeting, or possibly over lunch, decided that X milligrams per capsule sounded about right. Whether X milligrams delivers a pharmacologically relevant concentration of protopine or scoulerine to the human brain is a question that does not appear to have troubled anyone, which is the sort of oversight one might charitably describe as optimistic.

This is not unusual in the herbal supplement industry, but it is hardly rigorous, and one does rather wish the bottle would say so.

The Safety Profile, Such As It Is

The 2022 study tested seven phytochemicals from five commonly used herbal sleep aids, including protopine from California poppy. None of the compounds were genotoxic at 0.1 or 1 micromolar. Protopine did not affect cell viability, apoptosis, glucose consumption, lactate production, or cell differentiation at any tested concentration, which is to say it did absolutely nothing to the cells, good or bad. The authors concluded that it is likely safe, even during pregnancy, based on this in vitro work. Again, the qualifier 'likely', and the rather large assumption that cell culture results translate directly to human safety, an assumption that has occasionally been proven wrong in ways that made headlines.

A 2025 review of sleep management listed California poppy among a number of nutraceuticals with 'remarkable benefits', though it did not cite any human trials specific to California poppy alone, nor did it specify what constitutes a remarkable benefit, nor indeed what would constitute an unremarkable one. The paper notes that these remedies exert their effects through multiple mechanisms, both directly by modulating neurotransmitter and hormonal pathways, and indirectly by reducing stress, inflammation, and oxidative stress. This is a rather comprehensive list of mechanisms. A substance that does everything often does nothing particularly well, which is to say it is remarkable chiefly in its versatility on paper.

What One Can Reasonably Conclude

California poppy contains alkaloids that, in laboratory conditions, inhibit certain enzymes and bind to certain receptors associated with sleep regulation. In one unblinded observational trial, a combination of California poppy and valerian appeared to improve sleep outcomes in adults with adjustment insomnia, though the design does not allow anyone to determine how much of that improvement was due to California poppy specifically, how much to valerian, and how much to expectation. No study has established the oral bioavailability of the active alkaloids in humans. No study has measured their plasma concentrations after dosing. No study has determined an optimal dose based on pharmacokinetic data.

The California poppy supplement sitting on the shop shelf was dosed by guesswork, albeit informed guesswork, which is rather like saying the bridge was built by experienced amateurs. Its effects, if any, remain speculative.

People still take it. One simply ought not to expect that the dosing recommendations are based on the same sort of evidence one would expect from, say, a prescription medication, or indeed from a supplement that had been studied properly, with controls and a reasonable sample size and perhaps even a passing interest in whether the thing reaches the bloodstream. If you are comparing California poppy to melatonin for sleep, melatonin at least has been tested in humans at known doses with measurable outcomes, which is rather more than can be said for california poppy sleep research, and frankly sets a low bar that California poppy has not troubled itself to clear.

As for the best time to take California poppy, or where to buy it, those are questions for another day. Before worrying about timing or sourcing, it might be worth establishing whether the thing works at all, which would be the conventional order of operations.

This article is education and reporting on published research. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Talk to your own clinician about your own situation.

Sources

1. Integrative sleep management: from molecular pathways to conventional and herbal treatments, Naunyn-Schmiedeberg's archives of pharmacology (2025).
2. Comprehensive Metabolomic Profiling and Biological Activity Analysis of <i>Eschscholzia californica</i> Extracts Using LC-ESI-QTOF-MS, Food science & nutrition (2025).
3. Validated UHPLC Methods for Melatonin Quantification Reveal Regulatory Violations in EU Online Dietary Supplements Commerce, Molecules (Basel, Switzerland) (2025).
4. Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy, Frontiers in pharmacology (2022).
5. A combination of Eschscholtzia californica Cham. and Valeriana officinalis L. extracts for adjustment insomnia: A prospective observational study, Journal of traditional and complementary medicine (2020).